IgA Nephropathy (IgAN): Clinical Trials

12 trials for IgA Nephropathy (IgAN), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 3 active not recruiting, 2 not yet recruiting, 1 completed. 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 212Recruiting 4, Active not recruiting 3, Not yet recruiting 2, Completed 1, Enrolling by invitation 1, Terminated 1

Follow IgA Nephropathy (IgAN): new trials by email Literature Review of IgA Nephropathy (IgAN) trials Research Report on IgA Nephropathy (IgAN)

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SLN12140 in Adult Participants With IgA Nephropathy in China
SLN12140, Placebo - IgA Nephropathy (IgAN)
Phase 2Not yet recruitingLinno Pharmaceuticals, Inc.482026-05-292026-04-28
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
EVER001 - Minimal Change Disease (MCD), IgA Nephropathy (IgAN)
Phase 2RecruitingEverest Medicines (China) Co.,Ltd.452026-05-202026-08-05
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
RG002C0106, placebo subcutaneous administration - IgA Nephropathy (IgAN)
Phase 2Active not recruitingRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.302025-09-082026-10-13
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
ADX-038 Dose Level 2, ADX-038 Dose Level 1, ADX-038 Dose Level 3 - IgAN, C3G
Phase 2RecruitingADARx Pharmaceuticals, Inc.852025-08-282026-11-18
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
HSK39297 200mgQD, HSK39297 300mgQD - IgA Nephropathy (IgAN)
Phase 2RecruitingHaisco Pharmaceutical Group Co., Ltd.732025-08-252026-06-01
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Avacopan, Prednisone, Methylprednisolone (drug) - IgA Nephropathy (IgAN)
Phase 2RecruitingMayo Clinic162025-06-092026-10-09
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
SGB-9768 - IgA Nephropathy (IgAN), C3 Glomerulopathy
Phase 2Active not recruitingSuzhou Sanegene Bio Inc.452025-06-062026-09-04
Monthly Dosing of Atacicept in IgAN
Atacicept - IgA Nephropathy (IgAN), Berger Disease
Phase 2Active not recruitingVera Therapeutics, Inc.902025-05-292026-11-13
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
MY008211A tablets, MY008211A tablets matched placebo - IgA Nephropathy (IgAN)
Phase 2Not yet recruitingWuhan Createrna Science and Technology Co., Ltd722024-12-312024-11-18
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
Atacicept 150 mg - IgA Nephropathy (IgAN), Renal and Urinary Disorders
Phase 2Enrolling by invitationVera Therapeutics, Inc.7502024-12-012026-06-22
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Placebo, HSK39297 50mgBID, HSK39297 100mgBID - IgA Nephropathy (IgAN)
Phase 2CompletedHaisco Pharmaceutical Group Co., Ltd.872024-10-122026-05-28
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
Placebo, Cemdisiran - IgA Nephropathy (IgAN), Berger Disease
Phase 2TerminatedAlnylam Pharmaceuticals312019-09-302024-08-09

Narrower conditions

Glomerulonephritis, IGA (12)  ·  Glomerulosclerosis, Focal Segmental (1)  ·  Kidney Diseases (1)  ·  Nephrosis, Lipoid (1)  ·  Urologic Diseases (1)

Broader conditions

Autoimmune Diseases (12)  ·  Female Urogenital Diseases (12)  ·  Female Urogenital Diseases and Pregnancy Complications (12)  ·  Glomerulonephritis (12)  ·  Immune System Diseases (12)  ·  Male Urogenital Diseases (12)  ·  Nephritis (12)  ·  Urogenital Diseases (12)  ·  Kidney Diseases (11)  ·  Urologic Diseases (11)  ·  Nephrosis (1)

Interventions

TACI receptor-IgG Fc fragment fusion protein (2)  ·  Methylprednisolone (1)  ·  Pharmaceutical Preparations (1)  ·  Prednisolone (1)  ·  Prednisone (1)  ·  avacopan (1)

Sponsors

Haisco Pharmaceutical Group Co., Ltd. (2)  ·  Vera Therapeutics, Inc. (2)  ·  ADARx Pharmaceuticals, Inc. (1)  ·  Alnylam Pharmaceuticals (1)  ·  Everest Medicines (China) Co.,Ltd. (1)  ·  Linno Pharmaceuticals, Inc. (1)  ·  Mayo Clinic (1)  ·  Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. (1)  ·  Suzhou Sanegene Bio Inc. (1)  ·  Wuhan Createrna Science and Technology Co., Ltd (1)

Countries

China (7)  ·  United States (4)  ·  Spain (2)  ·  Taiwan (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Canada (1)  ·  France (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Philippines (1)  ·  Singapore (1)  ·  South Korea (1)  ·  Sweden (1)

Top investigators

Arezoo Mirad, MD (1)  ·  Eric Michael, MD (1)  ·  Fernando Fervenza, MD (1)  ·  Hong Zhang, PH.D. (1)  ·  Nabeel Aslam, MD (1)  ·  Zeeshan Khawaja (1)

NIH funding

2018 (1)